Biogen details Leqembi's gradual commercial ramp-up
Biogen recorded higher-than-expected revenue for the lead rare disease drug from its $7 billion acquisition of Reata Pharmaceuticals, but the rollout of its second-generation Alzheimer’s drug with Eisai is still a work in progress.
Leqembi, which received an accelerated nod last January and a full US approval last summer, is the first of the Alzheimer’s drugs that Medicare will pay for, and recent reports have said the anti-amyloid monoclonal antibody could cost Medicare billions by 2025. So far, the duo’s second shot at the memory-robbing disease after their first, Aduhelm, went up in smoke, has seen a slow commercial launch.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
